THE European Medicines Agency (EMA) announced today that it is recommending the approval of two new treatments for the disease caused by coronavirus, of «Xevudy(Sotrovimab) andKineret» (anakinra).
“Xevudy” (sotrovimab) is a medicine monoclonal antibody, intended for the treatment of COVID-19 in adults and adolescents (from 12 years and weighing at least 40 kg) who do not need supplemental oxygen and who are at increased risk to make the disease serious, broadcasts by ΑΠΕ ΜΠΕ.
“Kineret” (anakinra), again, is one immunosuppressive drug already approved in the European Union for the treatment of various inflammatory conditions. Its indication has now been expanded to include COVID-19 therapy in adult patients with pneumonia who need supplemental oxygen (low or high flow oxygen) and who are at risk of developing severe respiratory failure.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
